PA
ADPT icon

Perennial Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Perennial Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400
Closed -$16K – 88
2021
Q2 		$16K Hold
400
– – ﹤0.01% 221
2021
Q1 		$16K Buy
400
+200
+100% +$10.8K 0.01% 216
2020
Q4 		$12K Buy
+200
New +$10.3K ﹤0.01% 194

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Perennial Advisors's ADPT Position: Q3 2021 in Review

Perennial Advisors sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 400 shares — an estimated $16K sold.

Perennial Advisors first reported a position in ADPT in Q4 2020 and held it in 3 quarters. The position peaked at $16K in Q2 2021. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

  • Perennial Advisors reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Perennial Advisors sold 400 Adaptive Biotechnologies shares in Q3 2021, an estimated $16K.
  • Perennial Advisors first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 3 quarters.
  • Perennial Advisors's Adaptive Biotechnologies position peaked at $16K in Q2 2021.
  • 219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Perennial Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.